Human Coagulation Factor VIII Market Research Report from 2023 forecast to 2029, by Manufacturers, Regions, Type and Application

The global Human Coagulation Factor VIII market size was valued at USD 10530 million in 2022 and is forecast to a readjusted size of USD 15860 million by 2029 with a CAGR of 6.0% during review period.

Human Coagulation Factor VIII is an essential blood-clotting protein, also known as anti-hemophilic factor (AHF). In humans, factor VIII is encoded by the F8 gene, defects in this gene results in hemophilia A. Human Coagulation Factor VIII concentrated from donated blood plasma (Aafact or Alphanate, Monoclate-P®), or alternatively recombinant Human Coagulation Factor VIII can be given to hemophiliacs to restore hemostasis.

Global Human Coagulation Factor VIII key players include Baxter, Bayer, CSL, Pfizer, Biogen, etc. Global top five manufacturers hold a share about 80%. North America is the largest market, with a share about 60%, followed by Europe, with a share about 30 percent. In terms of product, Recombinant Factor VIII is the largest segment, with a share about 65%. And in terms of application, the largest application is Hemophilia A, followed by Spontanous / Trauma, Surgical, etc.

This report is a detailed and comprehensive analysis for global Human Coagulation Factor VIII market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:

Global Human Coagulation Factor VIII market size and forecasts, in consumption value ($ Million), sales quantity (K Bottles), and average selling prices (USD/Bottle), 2018-2029
Global Human Coagulation Factor VIII market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Bottles), and average selling prices (USD/Bottle), 2018-2029
Global Human Coagulation Factor VIII market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Bottles), and average selling prices (USD/Bottle), 2018-2029
Global Human Coagulation Factor VIII market shares of main players, shipments in revenue ($ Million), sales quantity (K Bottles), and ASP (USD/Bottle), 2018-2023

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Human Coagulation Factor VIII
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace

This report profiles key players in the global Human Coagulation Factor VIII market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

   Shire (Baxter)
   Bayer
   CSL
   Pfizer
   Grifols
   Biogen
   Octapharma
   NovoNordisk
   Greencross
   Kedrion
   BPL
   Hualan Bio
   RAAS

   Recombinant Factor VIII
   Plasma-derived Factor VIII

   Hemophilia A
   Spontanous / Trauma
   Surgical
   Other

   North America (United States, Canada and Mexico)
   Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
   Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
   South America (Brazil, Argentina, Colombia, and Rest of South America)
   Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

What are the strengths of the Human Coagulation Factor VIII Market in 2025?

The strengths include increasing awareness and diagnosis of hemophilia, advancements in genetic therapies, and a growing patient base due to better healthcare access globally. The market also benefits from innovations in recombinant factor VIII products that improve treatment efficacy and patient outcomes.

What are the weaknesses in this market?

High treatment costs, limited access in developing regions, and the dependency on continuous treatment can be seen as weaknesses. Moreover, the complexity of therapies, including storage and administration requirements, can create challenges for both patients and healthcare providers.

What opportunities exist for the Human Coagulation Factor VIII Market?

There are opportunities in expanding access to new therapies, particularly in emerging markets. Additionally, the ongoing research into gene therapy offers the potential for long-term treatment solutions, reducing reliance on regular factor VIII infusion therapies. Partnerships with biotechnology companies and ongoing clinical trials also present avenues for growth.

What are the threats facing the market?

Threats include the potential for market saturation as the number of treatment options increases, regulatory hurdles in approval processes, and competition from alternative therapies like gene therapy or non-factor treatments. Economic downturns could also impact healthcare spending, affecting patient access to critical treatments.

What are the political factors influencing the Human Coagulation Factor VIII Market in 2025?

Political factors include government policies on healthcare funding, reimbursement for hemophilia treatments, and regulations regarding drug approvals. Additionally, international trade agreements can impact the cost of imported factor VIII products, influencing market prices and accessibility.

What economic factors are affecting this market?

Economic factors like healthcare expenditure, insurance coverage, and the affordability of expensive treatments play a major role. Economic recessions or financial constraints in certain regions may reduce patient access to necessary therapies, affecting the growth of the market.

How do social factors impact the Human Coagulation Factor VIII Market?

Social factors include the rising awareness of hemophilia and genetic disorders, leading to earlier diagnoses and increasing demand for treatment. Furthermore, improving societal attitudes toward rare diseases and genetic therapies may enhance patient access to treatment options and contribute to market growth.

What technological advancements are influencing the market?

Technological advancements, such as the development of recombinant factor VIII therapies, gene therapy for hemophilia, and more efficient drug delivery systems, significantly impact the market. Innovations in biotechnology and genetics are expanding treatment options and offering potential for longer-term solutions to hemophilia.

What environmental factors are relevant to the market?

Environmental factors include the sustainability of raw materials used in factor VIII production and the need for eco-friendly manufacturing practices. Climate change and global health crises may also affect the logistics of drug distribution and the availability of treatments in affected regions.

What legal factors are shaping the market?

Legal factors include patent laws, intellectual property rights, and the regulation of drug approval processes. Stricter regulatory frameworks in certain countries may delay the availability of new treatments, while evolving patient protection laws can also affect market dynamics and the introduction of novel therapies.

Who are the suppliers in the Human Coagulation Factor VIII Market?

Suppliers include biotechnology and pharmaceutical companies that manufacture recombinant and plasma-derived factor VIII products. Key players also involve research institutions and genetic therapy developers that contribute to innovations in treatment.

What inputs are needed in the Human Coagulation Factor VIII Market?

The inputs required are high-quality raw materials, such as plasma or genetically engineered proteins for recombinant therapies. Research and development funding, manufacturing facilities, and skilled labor are also essential for producing factor VIII products.

Who are the process owners in this market?

Process owners include pharmaceutical companies responsible for the production, quality control, and distribution of factor VIII products. Regulatory bodies also play a crucial role in ensuring compliance with safety and efficacy standards for these therapies.

What outputs are generated in the Human Coagulation Factor VIII Market?

The outputs are the various forms of factor VIII therapies, including recombinant and plasma-derived products, as well as new advancements such as gene therapy treatments. These outputs aim to improve the management of hemophilia and other bleeding disorders.

Who are the customers in the Human Coagulation Factor VIII Market?

Customers include hospitals, clinics, healthcare providers, and individual patients suffering from hemophilia or other clotting disorders. Insurance companies and government healthcare programs also play a role as end customers by facilitating access to treatments.

What is the threat of new entrants in the Human Coagulation Factor VIII Market?

The threat of new entrants is relatively low due to the high barriers to entry, such as significant investment in research and development, regulatory hurdles, and the need for specialized manufacturing capabilities. The market is dominated by established players with strong patents and market experience.

How intense is the bargaining power of suppliers in this market?

The bargaining power of suppliers is moderate. While there are a few key suppliers of raw materials for factor VIII production, large pharmaceutical companies have the capability to negotiate favorable terms due to their scale and influence in the market.

What is the bargaining power of buyers in the Human Coagulation Factor VIII Market?

The bargaining power of buyers is relatively low. Patients typically have limited choices in treatment options, and healthcare providers may rely on specific suppliers or products. However, insurers and government healthcare programs hold some bargaining power when negotiating prices for bulk purchases.

How strong is the threat of substitute products in this market?

The threat of substitutes is moderate. While there are emerging alternatives like gene therapy and non-factor treatments, factor VIII products remain the standard treatment for hemophilia. The slow adoption of newer therapies and the high cost involved limits the immediate threat of substitutes.

How intense is the competitive rivalry in the Human Coagulation Factor VIII Market?

Competitive rivalry is high. The market is highly concentrated with a few dominant players, and the competition centers around product efficacy, cost, and innovations. Additionally, regulatory approvals and patient loyalty make it challenging for new players to capture significant market share.

What are the key upstream activities in the Human Coagulation Factor VIII Market?

Key upstream activities include the sourcing of raw materials, such as human plasma or recombinant DNA, and the research and development process. This involves biotech and pharmaceutical companies working on innovations in production methods, genetic modifications, and therapeutic approaches for factor VIII.

What are the challenges in upstream activities?

Challenges in upstream activities involve ensuring the quality and safety of raw materials, especially when sourcing from human plasma. Additionally, regulatory approvals for new technologies and the complexity of large-scale production of recombinant factor VIII products can cause delays and increase costs.

What role do suppliers play in upstream activities?

Suppliers are crucial in providing the necessary biological materials, enzymes, and chemicals for the manufacturing of factor VIII. They also supply the technology and expertise required for recombinant protein production and gene therapy advancements, which are essential in developing newer treatments.

How does innovation in upstream activities impact the market?

Innovation in upstream activities can significantly reduce production costs and increase the efficiency of factor VIII therapies. For example, advancements in gene therapy or the development of more efficient recombinant production systems can lead to more cost-effective and accessible treatment options, thus shaping market dynamics.

What are the key risks in upstream activities?

Key risks include the dependency on human plasma for sourcing factor VIII, which can face supply constraints or ethical concerns. Additionally, unforeseen regulatory hurdles, contamination risks during manufacturing, and the high costs of R&D in biotechnology represent significant challenges in the upstream supply chain.

What are the key midstream activities in the Human Coagulation Factor VIII Market?

Midstream activities primarily involve the manufacturing, production, and distribution of factor VIII products. This includes the scaling up of recombinant protein production, formulation into injectable therapies, packaging, and ensuring product stability for distribution.

What challenges exist in midstream activities?

Challenges in midstream activities include maintaining consistent product quality, managing the cold chain for storage and transportation, and meeting regulatory requirements for good manufacturing practices. Additionally, scaling production to meet growing demand while minimizing costs can be a complex balancing act.

How do manufacturers impact the midstream activities?

Manufacturers play a central role by ensuring the efficient production of high-quality factor VIII products. Their expertise in scaling production, optimizing processes, and maintaining compliance with regulations directly impacts the availability and cost-effectiveness of treatments in the market.

What are the key risks in midstream activities?

Key risks include supply chain disruptions, particularly for raw materials, and the potential for manufacturing delays due to regulatory issues or unforeseen technical problems. Additionally, fluctuations in demand or pricing pressures can impact profitability and distribution efficiency.

What role does technology play in midstream activities?

Technology plays a crucial role in enhancing the efficiency and scalability of factor VIII production. Automation, advanced bioprocessing techniques, and real-time monitoring systems help improve manufacturing speed, consistency, and product quality, which is critical for maintaining a steady supply of factor VIII therapies.

What are the key downstream activities in the Human Coagulation Factor VIII Market?

Downstream activities focus on the distribution, marketing, and administration of factor VIII products to patients. This includes the supply chain from manufacturers to hospitals, clinics, and pharmacies, along with patient support services such as education and adherence programs.

What challenges exist in downstream activities?

Challenges in downstream activities include ensuring timely delivery to patients, especially in remote or underserved regions. Additionally, the complexity of patient treatment plans and the need for personalized care can complicate effective distribution and administration.

How do healthcare providers impact the downstream activities?

Healthcare providers, including hospitals and clinics, are central to the downstream process by prescribing factor VIII therapies and monitoring patient response. They ensure proper administration and provide ongoing care to improve patient outcomes, which impacts the long-term success of treatments.

What are the key risks in downstream activities?

Key risks include supply chain disruptions, such as shortages or delays in shipping, as well as the financial barriers patients may face in accessing treatment. Additionally, market access restrictions due to regulatory changes or pricing pressures could affect the availability of factor VIII products.

What role does patient education play in downstream activities?

Patient education plays a crucial role in downstream activities, helping individuals understand their condition and treatment regimen. Providing clear instructions on medication administration, potential side effects, and the importance of consistent therapy adherence can improve treatment outcomes and overall market success.

Chapter 1, to describe Human Coagulation Factor VIII product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Human Coagulation Factor VIII, with price, sales, revenue and global market share of Human Coagulation Factor VIII from 2018 to 2023.
Chapter 3, the Human Coagulation Factor VIII competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Human Coagulation Factor VIII breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Human Coagulation Factor VIII market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Human Coagulation Factor VIII.
Chapter 14 and 15, to describe Human Coagulation Factor VIII sales channel, distributors, customers, research findings and conclusion.

1 Market Overview

   1.1 Product Overview and Scope of Human Coagulation Factor VIII
   1.2 Market Estimation Caveats and Base Year
   1.3 Market Analysis by Type
       1.3.1 Overview: Global Human Coagulation Factor VIII Consumption Value by Type: 2018 Versus 2022 Versus 2029
       1.3.2 Recombinant Factor VIII
       1.3.3 Plasma-derived Factor VIII
   1.4 Market Analysis by Application
       1.4.1 Overview: Global Human Coagulation Factor VIII Consumption Value by Application: 2018 Versus 2022 Versus 2029
       1.4.2 Hemophilia A
       1.4.3 Spontanous / Trauma
       1.4.4 Surgical
       1.4.5 Other
   1.5 Global Human Coagulation Factor VIII Market Size & Forecast
       1.5.1 Global Human Coagulation Factor VIII Consumption Value (2018 & 2022 & 2029)
       1.5.2 Global Human Coagulation Factor VIII Sales Quantity (2018-2029)
       1.5.3 Global Human Coagulation Factor VIII Average Price (2018-2029)

2 Manufacturers Profiles

   2.1 Shire (Baxter)
       2.1.1 Shire (Baxter) Details
       2.1.2 Shire (Baxter) Major Business
       2.1.3 Shire (Baxter) Human Coagulation Factor VIII Product and Services
       2.1.4 Shire (Baxter) Human Coagulation Factor VIII Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.1.5 Shire (Baxter) Recent Developments/Updates
   2.2 Bayer
       2.2.1 Bayer Details
       2.2.2 Bayer Major Business
       2.2.3 Bayer Human Coagulation Factor VIII Product and Services
       2.2.4 Bayer Human Coagulation Factor VIII Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.2.5 Bayer Recent Developments/Updates
   2.3 CSL
       2.3.1 CSL Details
       2.3.2 CSL Major Business
       2.3.3 CSL Human Coagulation Factor VIII Product and Services
       2.3.4 CSL Human Coagulation Factor VIII Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.3.5 CSL Recent Developments/Updates
   2.4 Pfizer
       2.4.1 Pfizer Details
       2.4.2 Pfizer Major Business
       2.4.3 Pfizer Human Coagulation Factor VIII Product and Services
       2.4.4 Pfizer Human Coagulation Factor VIII Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.4.5 Pfizer Recent Developments/Updates
   2.5 Grifols
       2.5.1 Grifols Details
       2.5.2 Grifols Major Business
       2.5.3 Grifols Human Coagulation Factor VIII Product and Services
       2.5.4 Grifols Human Coagulation Factor VIII Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.5.5 Grifols Recent Developments/Updates
   2.6 Biogen
       2.6.1 Biogen Details
       2.6.2 Biogen Major Business
       2.6.3 Biogen Human Coagulation Factor VIII Product and Services
       2.6.4 Biogen Human Coagulation Factor VIII Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.6.5 Biogen Recent Developments/Updates
   2.7 Octapharma
       2.7.1 Octapharma Details
       2.7.2 Octapharma Major Business
       2.7.3 Octapharma Human Coagulation Factor VIII Product and Services
       2.7.4 Octapharma Human Coagulation Factor VIII Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.7.5 Octapharma Recent Developments/Updates
   2.8 NovoNordisk
       2.8.1 NovoNordisk Details
       2.8.2 NovoNordisk Major Business
       2.8.3 NovoNordisk Human Coagulation Factor VIII Product and Services
       2.8.4 NovoNordisk Human Coagulation Factor VIII Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.8.5 NovoNordisk Recent Developments/Updates
   2.9 Greencross
       2.9.1 Greencross Details
       2.9.2 Greencross Major Business
       2.9.3 Greencross Human Coagulation Factor VIII Product and Services
       2.9.4 Greencross Human Coagulation Factor VIII Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.9.5 Greencross Recent Developments/Updates
   2.10 Kedrion
       2.10.1 Kedrion Details
       2.10.2 Kedrion Major Business
       2.10.3 Kedrion Human Coagulation Factor VIII Product and Services
       2.10.4 Kedrion Human Coagulation Factor VIII Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.10.5 Kedrion Recent Developments/Updates
   2.11 BPL
       2.11.1 BPL Details
       2.11.2 BPL Major Business
       2.11.3 BPL Human Coagulation Factor VIII Product and Services
       2.11.4 BPL Human Coagulation Factor VIII Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.11.5 BPL Recent Developments/Updates
   2.12 Hualan Bio
       2.12.1 Hualan Bio Details
       2.12.2 Hualan Bio Major Business
       2.12.3 Hualan Bio Human Coagulation Factor VIII Product and Services
       2.12.4 Hualan Bio Human Coagulation Factor VIII Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.12.5 Hualan Bio Recent Developments/Updates
   2.13 RAAS
       2.13.1 RAAS Details
       2.13.2 RAAS Major Business
       2.13.3 RAAS Human Coagulation Factor VIII Product and Services
       2.13.4 RAAS Human Coagulation Factor VIII Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.13.5 RAAS Recent Developments/Updates

3 Competitive Environment: Human Coagulation Factor VIII by Manufacturer

   3.1 Global Human Coagulation Factor VIII Sales Quantity by Manufacturer (2018-2023)
   3.2 Global Human Coagulation Factor VIII Revenue by Manufacturer (2018-2023)
   3.3 Global Human Coagulation Factor VIII Average Price by Manufacturer (2018-2023)
   3.4 Market Share Analysis (2022)
       3.4.1 Producer Shipments of Human Coagulation Factor VIII by Manufacturer Revenue ($MM) and Market Share (%): 2022
       3.4.2 Top 3 Human Coagulation Factor VIII Manufacturer Market Share in 2022
       3.4.2 Top 6 Human Coagulation Factor VIII Manufacturer Market Share in 2022
   3.5 Human Coagulation Factor VIII Market: Overall Company Footprint Analysis
       3.5.1 Human Coagulation Factor VIII Market: Region Footprint
       3.5.2 Human Coagulation Factor VIII Market: Company Product Type Footprint
       3.5.3 Human Coagulation Factor VIII Market: Company Product Application Footprint
   3.6 New Market Entrants and Barriers to Market Entry
   3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

   4.1 Global Human Coagulation Factor VIII Market Size by Region
       4.1.1 Global Human Coagulation Factor VIII Sales Quantity by Region (2018-2029)
       4.1.2 Global Human Coagulation Factor VIII Consumption Value by Region (2018-2029)
       4.1.3 Global Human Coagulation Factor VIII Average Price by Region (2018-2029)
   4.2 North America Human Coagulation Factor VIII Consumption Value (2018-2029)
   4.3 Europe Human Coagulation Factor VIII Consumption Value (2018-2029)
   4.4 Asia-Pacific Human Coagulation Factor VIII Consumption Value (2018-2029)
   4.5 South America Human Coagulation Factor VIII Consumption Value (2018-2029)
   4.6 Middle East and Africa Human Coagulation Factor VIII Consumption Value (2018-2029)

5 Market Segment by Type

   5.1 Global Human Coagulation Factor VIII Sales Quantity by Type (2018-2029)
   5.2 Global Human Coagulation Factor VIII Consumption Value by Type (2018-2029)
   5.3 Global Human Coagulation Factor VIII Average Price by Type (2018-2029)

6 Market Segment by Application

   6.1 Global Human Coagulation Factor VIII Sales Quantity by Application (2018-2029)
   6.2 Global Human Coagulation Factor VIII Consumption Value by Application (2018-2029)
   6.3 Global Human Coagulation Factor VIII Average Price by Application (2018-2029)

7 North America

   7.1 North America Human Coagulation Factor VIII Sales Quantity by Type (2018-2029)
   7.2 North America Human Coagulation Factor VIII Sales Quantity by Application (2018-2029)
   7.3 North America Human Coagulation Factor VIII Market Size by Country
       7.3.1 North America Human Coagulation Factor VIII Sales Quantity by Country (2018-2029)
       7.3.2 North America Human Coagulation Factor VIII Consumption Value by Country (2018-2029)
       7.3.3 United States Market Size and Forecast (2018-2029)
       7.3.4 Canada Market Size and Forecast (2018-2029)
       7.3.5 Mexico Market Size and Forecast (2018-2029)

8 Europe

   8.1 Europe Human Coagulation Factor VIII Sales Quantity by Type (2018-2029)
   8.2 Europe Human Coagulation Factor VIII Sales Quantity by Application (2018-2029)
   8.3 Europe Human Coagulation Factor VIII Market Size by Country
       8.3.1 Europe Human Coagulation Factor VIII Sales Quantity by Country (2018-2029)
       8.3.2 Europe Human Coagulation Factor VIII Consumption Value by Country (2018-2029)
       8.3.3 Germany Market Size and Forecast (2018-2029)
       8.3.4 France Market Size and Forecast (2018-2029)
       8.3.5 United Kingdom Market Size and Forecast (2018-2029)
       8.3.6 Russia Market Size and Forecast (2018-2029)
       8.3.7 Italy Market Size and Forecast (2018-2029)

9 Asia-Pacific

   9.1 Asia-Pacific Human Coagulation Factor VIII Sales Quantity by Type (2018-2029)
   9.2 Asia-Pacific Human Coagulation Factor VIII Sales Quantity by Application (2018-2029)
   9.3 Asia-Pacific Human Coagulation Factor VIII Market Size by Region
       9.3.1 Asia-Pacific Human Coagulation Factor VIII Sales Quantity by Region (2018-2029)
       9.3.2 Asia-Pacific Human Coagulation Factor VIII Consumption Value by Region (2018-2029)
       9.3.3 China Market Size and Forecast (2018-2029)
       9.3.4 Japan Market Size and Forecast (2018-2029)
       9.3.5 Korea Market Size and Forecast (2018-2029)
       9.3.6 India Market Size and Forecast (2018-2029)
       9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
       9.3.8 Australia Market Size and Forecast (2018-2029)

10 South America

   10.1 South America Human Coagulation Factor VIII Sales Quantity by Type (2018-2029)
   10.2 South America Human Coagulation Factor VIII Sales Quantity by Application (2018-2029)
   10.3 South America Human Coagulation Factor VIII Market Size by Country
       10.3.1 South America Human Coagulation Factor VIII Sales Quantity by Country (2018-2029)
       10.3.2 South America Human Coagulation Factor VIII Consumption Value by Country (2018-2029)
       10.3.3 Brazil Market Size and Forecast (2018-2029)
       10.3.4 Argentina Market Size and Forecast (2018-2029)

11 Middle East & Africa

   11.1 Middle East & Africa Human Coagulation Factor VIII Sales Quantity by Type (2018-2029)
   11.2 Middle East & Africa Human Coagulation Factor VIII Sales Quantity by Application (2018-2029)
   11.3 Middle East & Africa Human Coagulation Factor VIII Market Size by Country
       11.3.1 Middle East & Africa Human Coagulation Factor VIII Sales Quantity by Country (2018-2029)
       11.3.2 Middle East & Africa Human Coagulation Factor VIII Consumption Value by Country (2018-2029)
       11.3.3 Turkey Market Size and Forecast (2018-2029)
       11.3.4 Egypt Market Size and Forecast (2018-2029)
       11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
       11.3.6 South Africa Market Size and Forecast (2018-2029)

12 Market Dynamics

   12.1 Human Coagulation Factor VIII Market Drivers
   12.2 Human Coagulation Factor VIII Market Restraints
   12.3 Human Coagulation Factor VIII Trends Analysis
   12.4 Porters Five Forces Analysis
       12.4.1 Threat of New Entrants
       12.4.2 Bargaining Power of Suppliers
       12.4.3 Bargaining Power of Buyers
       12.4.4 Threat of Substitutes
       12.4.5 Competitive Rivalry
   12.5 Influence of COVID-19 and Russia-Ukraine War
       12.5.1 Influence of COVID-19
       12.5.2 Influence of Russia-Ukraine War

13 Raw Material and Industry Chain

   13.1 Raw Material of Human Coagulation Factor VIII and Key Manufacturers
   13.2 Manufacturing Costs Percentage of Human Coagulation Factor VIII
   13.3 Human Coagulation Factor VIII Production Process
   13.4 Human Coagulation Factor VIII Industrial Chain

14 Shipments by Distribution Channel

   14.1 Sales Channel
       14.1.1 Direct to End-User
       14.1.2 Distributors
   14.2 Human Coagulation Factor VIII Typical Distributors
   14.3 Human Coagulation Factor VIII Typical Customers

15 Research Findings and Conclusion

16 Appendix

   16.1 Methodology
   16.2 Research Process and Data Source
   16.3 Disclaimer

List of Tables

   Table 1. Global Human Coagulation Factor VIII Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
   Table 2. Global Human Coagulation Factor VIII Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
   Table 3. Shire (Baxter) Basic Information, Manufacturing Base and Competitors
   Table 4. Shire (Baxter) Major Business
   Table 5. Shire (Baxter) Human Coagulation Factor VIII Product and Services
   Table 6. Shire (Baxter) Human Coagulation Factor VIII Sales Quantity (K Bottles), Average Price (USD/Bottle), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 7. Shire (Baxter) Recent Developments/Updates
   Table 8. Bayer Basic Information, Manufacturing Base and Competitors
   Table 9. Bayer Major Business
   Table 10. Bayer Human Coagulation Factor VIII Product and Services
   Table 11. Bayer Human Coagulation Factor VIII Sales Quantity (K Bottles), Average Price (USD/Bottle), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 12. Bayer Recent Developments/Updates
   Table 13. CSL Basic Information, Manufacturing Base and Competitors
   Table 14. CSL Major Business
   Table 15. CSL Human Coagulation Factor VIII Product and Services
   Table 16. CSL Human Coagulation Factor VIII Sales Quantity (K Bottles), Average Price (USD/Bottle), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 17. CSL Recent Developments/Updates
   Table 18. Pfizer Basic Information, Manufacturing Base and Competitors
   Table 19. Pfizer Major Business
   Table 20. Pfizer Human Coagulation Factor VIII Product and Services
   Table 21. Pfizer Human Coagulation Factor VIII Sales Quantity (K Bottles), Average Price (USD/Bottle), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 22. Pfizer Recent Developments/Updates
   Table 23. Grifols Basic Information, Manufacturing Base and Competitors
   Table 24. Grifols Major Business
   Table 25. Grifols Human Coagulation Factor VIII Product and Services
   Table 26. Grifols Human Coagulation Factor VIII Sales Quantity (K Bottles), Average Price (USD/Bottle), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 27. Grifols Recent Developments/Updates
   Table 28. Biogen Basic Information, Manufacturing Base and Competitors
   Table 29. Biogen Major Business
   Table 30. Biogen Human Coagulation Factor VIII Product and Services
   Table 31. Biogen Human Coagulation Factor VIII Sales Quantity (K Bottles), Average Price (USD/Bottle), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 32. Biogen Recent Developments/Updates
   Table 33. Octapharma Basic Information, Manufacturing Base and Competitors
   Table 34. Octapharma Major Business
   Table 35. Octapharma Human Coagulation Factor VIII Product and Services
   Table 36. Octapharma Human Coagulation Factor VIII Sales Quantity (K Bottles), Average Price (USD/Bottle), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 37. Octapharma Recent Developments/Updates
   Table 38. NovoNordisk Basic Information, Manufacturing Base and Competitors
   Table 39. NovoNordisk Major Business
   Table 40. NovoNordisk Human Coagulation Factor VIII Product and Services
   Table 41. NovoNordisk Human Coagulation Factor VIII Sales Quantity (K Bottles), Average Price (USD/Bottle), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 42. NovoNordisk Recent Developments/Updates
   Table 43. Greencross Basic Information, Manufacturing Base and Competitors
   Table 44. Greencross Major Business
   Table 45. Greencross Human Coagulation Factor VIII Product and Services
   Table 46. Greencross Human Coagulation Factor VIII Sales Quantity (K Bottles), Average Price (USD/Bottle), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 47. Greencross Recent Developments/Updates
   Table 48. Kedrion Basic Information, Manufacturing Base and Competitors
   Table 49. Kedrion Major Business
   Table 50. Kedrion Human Coagulation Factor VIII Product and Services
   Table 51. Kedrion Human Coagulation Factor VIII Sales Quantity (K Bottles), Average Price (USD/Bottle), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 52. Kedrion Recent Developments/Updates
   Table 53. BPL Basic Information, Manufacturing Base and Competitors
   Table 54. BPL Major Business
   Table 55. BPL Human Coagulation Factor VIII Product and Services
   Table 56. BPL Human Coagulation Factor VIII Sales Quantity (K Bottles), Average Price (USD/Bottle), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 57. BPL Recent Developments/Updates
   Table 58. Hualan Bio Basic Information, Manufacturing Base and Competitors
   Table 59. Hualan Bio Major Business
   Table 60. Hualan Bio Human Coagulation Factor VIII Product and Services
   Table 61. Hualan Bio Human Coagulation Factor VIII Sales Quantity (K Bottles), Average Price (USD/Bottle), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 62. Hualan Bio Recent Developments/Updates
   Table 63. RAAS Basic Information, Manufacturing Base and Competitors
   Table 64. RAAS Major Business
   Table 65. RAAS Human Coagulation Factor VIII Product and Services
   Table 66. RAAS Human Coagulation Factor VIII Sales Quantity (K Bottles), Average Price (USD/Bottle), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 67. RAAS Recent Developments/Updates
   Table 68. Global Human Coagulation Factor VIII Sales Quantity by Manufacturer (2018-2023) & (K Bottles)
   Table 69. Global Human Coagulation Factor VIII Revenue by Manufacturer (2018-2023) & (USD Million)
   Table 70. Global Human Coagulation Factor VIII Average Price by Manufacturer (2018-2023) & (USD/Bottle)
   Table 71. Market Position of Manufacturers in Human Coagulation Factor VIII, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
   Table 72. Head Office and Human Coagulation Factor VIII Production Site of Key Manufacturer
   Table 73. Human Coagulation Factor VIII Market: Company Product Type Footprint
   Table 74. Human Coagulation Factor VIII Market: Company Product Application Footprint
   Table 75. Human Coagulation Factor VIII New Market Entrants and Barriers to Market Entry
   Table 76. Human Coagulation Factor VIII Mergers, Acquisition, Agreements, and Collaborations
   Table 77. Global Human Coagulation Factor VIII Sales Quantity by Region (2018-2023) & (K Bottles)
   Table 78. Global Human Coagulation Factor VIII Sales Quantity by Region (2024-2029) & (K Bottles)
   Table 79. Global Human Coagulation Factor VIII Consumption Value by Region (2018-2023) & (USD Million)
   Table 80. Global Human Coagulation Factor VIII Consumption Value by Region (2024-2029) & (USD Million)
   Table 81. Global Human Coagulation Factor VIII Average Price by Region (2018-2023) & (USD/Bottle)
   Table 82. Global Human Coagulation Factor VIII Average Price by Region (2024-2029) & (USD/Bottle)
   Table 83. Global Human Coagulation Factor VIII Sales Quantity by Type (2018-2023) & (K Bottles)
   Table 84. Global Human Coagulation Factor VIII Sales Quantity by Type (2024-2029) & (K Bottles)
   Table 85. Global Human Coagulation Factor VIII Consumption Value by Type (2018-2023) & (USD Million)
   Table 86. Global Human Coagulation Factor VIII Consumption Value by Type (2024-2029) & (USD Million)
   Table 87. Global Human Coagulation Factor VIII Average Price by Type (2018-2023) & (USD/Bottle)
   Table 88. Global Human Coagulation Factor VIII Average Price by Type (2024-2029) & (USD/Bottle)
   Table 89. Global Human Coagulation Factor VIII Sales Quantity by Application (2018-2023) & (K Bottles)
   Table 90. Global Human Coagulation Factor VIII Sales Quantity by Application (2024-2029) & (K Bottles)
   Table 91. Global Human Coagulation Factor VIII Consumption Value by Application (2018-2023) & (USD Million)
   Table 92. Global Human Coagulation Factor VIII Consumption Value by Application (2024-2029) & (USD Million)
   Table 93. Global Human Coagulation Factor VIII Average Price by Application (2018-2023) & (USD/Bottle)
   Table 94. Global Human Coagulation Factor VIII Average Price by Application (2024-2029) & (USD/Bottle)
   Table 95. North America Human Coagulation Factor VIII Sales Quantity by Type (2018-2023) & (K Bottles)
   Table 96. North America Human Coagulation Factor VIII Sales Quantity by Type (2024-2029) & (K Bottles)
   Table 97. North America Human Coagulation Factor VIII Sales Quantity by Application (2018-2023) & (K Bottles)
   Table 98. North America Human Coagulation Factor VIII Sales Quantity by Application (2024-2029) & (K Bottles)
   Table 99. North America Human Coagulation Factor VIII Sales Quantity by Country (2018-2023) & (K Bottles)
   Table 100. North America Human Coagulation Factor VIII Sales Quantity by Country (2024-2029) & (K Bottles)
   Table 101. North America Human Coagulation Factor VIII Consumption Value by Country (2018-2023) & (USD Million)
   Table 102. North America Human Coagulation Factor VIII Consumption Value by Country (2024-2029) & (USD Million)
   Table 103. Europe Human Coagulation Factor VIII Sales Quantity by Type (2018-2023) & (K Bottles)
   Table 104. Europe Human Coagulation Factor VIII Sales Quantity by Type (2024-2029) & (K Bottles)
   Table 105. Europe Human Coagulation Factor VIII Sales Quantity by Application (2018-2023) & (K Bottles)
   Table 106. Europe Human Coagulation Factor VIII Sales Quantity by Application (2024-2029) & (K Bottles)
   Table 107. Europe Human Coagulation Factor VIII Sales Quantity by Country (2018-2023) & (K Bottles)
   Table 108. Europe Human Coagulation Factor VIII Sales Quantity by Country (2024-2029) & (K Bottles)
   Table 109. Europe Human Coagulation Factor VIII Consumption Value by Country (2018-2023) & (USD Million)
   Table 110. Europe Human Coagulation Factor VIII Consumption Value by Country (2024-2029) & (USD Million)
   Table 111. Asia-Pacific Human Coagulation Factor VIII Sales Quantity by Type (2018-2023) & (K Bottles)
   Table 112. Asia-Pacific Human Coagulation Factor VIII Sales Quantity by Type (2024-2029) & (K Bottles)
   Table 113. Asia-Pacific Human Coagulation Factor VIII Sales Quantity by Application (2018-2023) & (K Bottles)
   Table 114. Asia-Pacific Human Coagulation Factor VIII Sales Quantity by Application (2024-2029) & (K Bottles)
   Table 115. Asia-Pacific Human Coagulation Factor VIII Sales Quantity by Region (2018-2023) & (K Bottles)
   Table 116. Asia-Pacific Human Coagulation Factor VIII Sales Quantity by Region (2024-2029) & (K Bottles)
   Table 117. Asia-Pacific Human Coagulation Factor VIII Consumption Value by Region (2018-2023) & (USD Million)
   Table 118. Asia-Pacific Human Coagulation Factor VIII Consumption Value by Region (2024-2029) & (USD Million)
   Table 119. South America Human Coagulation Factor VIII Sales Quantity by Type (2018-2023) & (K Bottles)
   Table 120. South America Human Coagulation Factor VIII Sales Quantity by Type (2024-2029) & (K Bottles)
   Table 121. South America Human Coagulation Factor VIII Sales Quantity by Application (2018-2023) & (K Bottles)
   Table 122. South America Human Coagulation Factor VIII Sales Quantity by Application (2024-2029) & (K Bottles)
   Table 123. South America Human Coagulation Factor VIII Sales Quantity by Country (2018-2023) & (K Bottles)
   Table 124. South America Human Coagulation Factor VIII Sales Quantity by Country (2024-2029) & (K Bottles)
   Table 125. South America Human Coagulation Factor VIII Consumption Value by Country (2018-2023) & (USD Million)
   Table 126. South America Human Coagulation Factor VIII Consumption Value by Country (2024-2029) & (USD Million)
   Table 127. Middle East & Africa Human Coagulation Factor VIII Sales Quantity by Type (2018-2023) & (K Bottles)
   Table 128. Middle East & Africa Human Coagulation Factor VIII Sales Quantity by Type (2024-2029) & (K Bottles)
   Table 129. Middle East & Africa Human Coagulation Factor VIII Sales Quantity by Application (2018-2023) & (K Bottles)
   Table 130. Middle East & Africa Human Coagulation Factor VIII Sales Quantity by Application (2024-2029) & (K Bottles)
   Table 131. Middle East & Africa Human Coagulation Factor VIII Sales Quantity by Region (2018-2023) & (K Bottles)
   Table 132. Middle East & Africa Human Coagulation Factor VIII Sales Quantity by Region (2024-2029) & (K Bottles)
   Table 133. Middle East & Africa Human Coagulation Factor VIII Consumption Value by Region (2018-2023) & (USD Million)
   Table 134. Middle East & Africa Human Coagulation Factor VIII Consumption Value by Region (2024-2029) & (USD Million)
   Table 135. Human Coagulation Factor VIII Raw Material
   Table 136. Key Manufacturers of Human Coagulation Factor VIII Raw Materials
   Table 137. Human Coagulation Factor VIII Typical Distributors
   Table 138. Human Coagulation Factor VIII Typical Customers

List of Figures

   Figure 1. Human Coagulation Factor VIII Picture
   Figure 2. Global Human Coagulation Factor VIII Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
   Figure 3. Global Human Coagulation Factor VIII Consumption Value Market Share by Type in 2022
   Figure 4. Recombinant Factor VIII Examples
   Figure 5. Plasma-derived Factor VIII Examples
   Figure 6. Global Human Coagulation Factor VIII Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
   Figure 7. Global Human Coagulation Factor VIII Consumption Value Market Share by Application in 2022
   Figure 8. Hemophilia A Examples
   Figure 9. Spontanous / Trauma Examples
   Figure 10. Surgical Examples
   Figure 11. Other Examples
   Figure 12. Global Human Coagulation Factor VIII Consumption Value, (USD Million): 2018 & 2022 & 2029
   Figure 13. Global Human Coagulation Factor VIII Consumption Value and Forecast (2018-2029) & (USD Million)
   Figure 14. Global Human Coagulation Factor VIII Sales Quantity (2018-2029) & (K Bottles)
   Figure 15. Global Human Coagulation Factor VIII Average Price (2018-2029) & (USD/Bottle)
   Figure 16. Global Human Coagulation Factor VIII Sales Quantity Market Share by Manufacturer in 2022
   Figure 17. Global Human Coagulation Factor VIII Consumption Value Market Share by Manufacturer in 2022
   Figure 18. Producer Shipments of Human Coagulation Factor VIII by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
   Figure 19. Top 3 Human Coagulation Factor VIII Manufacturer (Consumption Value) Market Share in 2022
   Figure 20. Top 6 Human Coagulation Factor VIII Manufacturer (Consumption Value) Market Share in 2022
   Figure 21. Global Human Coagulation Factor VIII Sales Quantity Market Share by Region (2018-2029)
   Figure 22. Global Human Coagulation Factor VIII Consumption Value Market Share by Region (2018-2029)
   Figure 23. North America Human Coagulation Factor VIII Consumption Value (2018-2029) & (USD Million)
   Figure 24. Europe Human Coagulation Factor VIII Consumption Value (2018-2029) & (USD Million)
   Figure 25. Asia-Pacific Human Coagulation Factor VIII Consumption Value (2018-2029) & (USD Million)
   Figure 26. South America Human Coagulation Factor VIII Consumption Value (2018-2029) & (USD Million)
   Figure 27. Middle East & Africa Human Coagulation Factor VIII Consumption Value (2018-2029) & (USD Million)
   Figure 28. Global Human Coagulation Factor VIII Sales Quantity Market Share by Type (2018-2029)
   Figure 29. Global Human Coagulation Factor VIII Consumption Value Market Share by Type (2018-2029)
   Figure 30. Global Human Coagulation Factor VIII Average Price by Type (2018-2029) & (USD/Bottle)
   Figure 31. Global Human Coagulation Factor VIII Sales Quantity Market Share by Application (2018-2029)
   Figure 32. Global Human Coagulation Factor VIII Consumption Value Market Share by Application (2018-2029)
   Figure 33. Global Human Coagulation Factor VIII Average Price by Application (2018-2029) & (USD/Bottle)
   Figure 34. North America Human Coagulation Factor VIII Sales Quantity Market Share by Type (2018-2029)
   Figure 35. North America Human Coagulation Factor VIII Sales Quantity Market Share by Application (2018-2029)
   Figure 36. North America Human Coagulation Factor VIII Sales Quantity Market Share by Country (2018-2029)
   Figure 37. North America Human Coagulation Factor VIII Consumption Value Market Share by Country (2018-2029)
   Figure 38. United States Human Coagulation Factor VIII Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 39. Canada Human Coagulation Factor VIII Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 40. Mexico Human Coagulation Factor VIII Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 41. Europe Human Coagulation Factor VIII Sales Quantity Market Share by Type (2018-2029)
   Figure 42. Europe Human Coagulation Factor VIII Sales Quantity Market Share by Application (2018-2029)
   Figure 43. Europe Human Coagulation Factor VIII Sales Quantity Market Share by Country (2018-2029)
   Figure 44. Europe Human Coagulation Factor VIII Consumption Value Market Share by Country (2018-2029)
   Figure 45. Germany Human Coagulation Factor VIII Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 46. France Human Coagulation Factor VIII Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 47. United Kingdom Human Coagulation Factor VIII Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 48. Russia Human Coagulation Factor VIII Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 49. Italy Human Coagulation Factor VIII Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 50. Asia-Pacific Human Coagulation Factor VIII Sales Quantity Market Share by Type (2018-2029)
   Figure 51. Asia-Pacific Human Coagulation Factor VIII Sales Quantity Market Share by Application (2018-2029)
   Figure 52. Asia-Pacific Human Coagulation Factor VIII Sales Quantity Market Share by Region (2018-2029)
   Figure 53. Asia-Pacific Human Coagulation Factor VIII Consumption Value Market Share by Region (2018-2029)
   Figure 54. China Human Coagulation Factor VIII Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 55. Japan Human Coagulation Factor VIII Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 56. Korea Human Coagulation Factor VIII Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 57. India Human Coagulation Factor VIII Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 58. Southeast Asia Human Coagulation Factor VIII Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 59. Australia Human Coagulation Factor VIII Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 60. South America Human Coagulation Factor VIII Sales Quantity Market Share by Type (2018-2029)
   Figure 61. South America Human Coagulation Factor VIII Sales Quantity Market Share by Application (2018-2029)
   Figure 62. South America Human Coagulation Factor VIII Sales Quantity Market Share by Country (2018-2029)
   Figure 63. South America Human Coagulation Factor VIII Consumption Value Market Share by Country (2018-2029)
   Figure 64. Brazil Human Coagulation Factor VIII Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 65. Argentina Human Coagulation Factor VIII Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 66. Middle East & Africa Human Coagulation Factor VIII Sales Quantity Market Share by Type (2018-2029)
   Figure 67. Middle East & Africa Human Coagulation Factor VIII Sales Quantity Market Share by Application (2018-2029)
   Figure 68. Middle East & Africa Human Coagulation Factor VIII Sales Quantity Market Share by Region (2018-2029)
   Figure 69. Middle East & Africa Human Coagulation Factor VIII Consumption Value Market Share by Region (2018-2029)
   Figure 70. Turkey Human Coagulation Factor VIII Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 71. Egypt Human Coagulation Factor VIII Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 72. Saudi Arabia Human Coagulation Factor VIII Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 73. South Africa Human Coagulation Factor VIII Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 74. Human Coagulation Factor VIII Market Drivers
   Figure 75. Human Coagulation Factor VIII Market Restraints
   Figure 76. Human Coagulation Factor VIII Market Trends
   Figure 77. Porters Five Forces Analysis
   Figure 78. Manufacturing Cost Structure Analysis of Human Coagulation Factor VIII in 2022
   Figure 79. Manufacturing Process Analysis of Human Coagulation Factor VIII
   Figure 80. Human Coagulation Factor VIII Industrial Chain
   Figure 81. Sales Quantity Channel: Direct to End-User vs Distributors
   Figure 82. Direct Channel Pros & Cons
   Figure 83. Indirect Channel Pros & Cons
   Figure 84. Methodology
   Figure 85. Research Process and Data Source